Literature DB >> 19410572

Serum free light chain analysis may miss monoclonal light chains that urine immunofixation electrophoreses would detect.

Saad P Shaheen1, Stanley S Levinson.   

Abstract

BACKGROUND: A nephelometric assay for identifying free light chains (FLC) of immunoglobulin in serum is commercially available. Although this assay is not specific for monoclonal FLC, an abnormal kappa/lambda ratio is thought to presumptively identify monoclonal FLCs. It has been proposed that serum FLC assays can replace urine immunofixation electrophoresis (IFE) for routine detection. This proposal seems to be based upon testing of samples retrospectively drawn from patients mostly with myeloma or known primary amyloidosis-conditions that are less frequently observed in general laboratory practice.
METHODS: Prospective analysis of 5 patient samples by standard care techniques with serum/urine IFE compared with serum FLC nephelometric assay. Rather than classical myeloma, cases were selected on the basis of unusual or equivocal atypical serum protein electrophoresis patterns.
RESULTS: In all 5 cases, the nephelometric method for free light chains was negative by virtue of serum FLC kappa/lambda ratio being within the reference range, contrasting with monoclonal proteins or free light chains detected by serum/urine IFE.
CONCLUSIONS: Since peculiar or unusual patterns are more commonly observed in general practice, these cases illustrate the pitfalls of relying solely on the serum free light chain analysis method in order to establish the presence of monoclonal FLC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19410572     DOI: 10.1016/j.cca.2009.04.024

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  7 in total

1.  Monoclonal Light Chains Can Remain Unnoticed in Protein Electrophoresis.

Authors:  Hamit Yasar Ellidag; Esin Eren; Ozgur Aydin; Necat Yilmaz
Journal:  Indian J Clin Biochem       Date:  2015-02-28

2.  Defining the impact of individual sample variability on routine immunoassay of serum free light chains (sFLC) in multiple myeloma.

Authors:  S H K Murng; L Follows; P Whitfield; J A Snowden; K Swallow; K Green; R Sargur; W Egner
Journal:  Clin Exp Immunol       Date:  2013-02       Impact factor: 4.330

Review 3.  Current state of the art for enhancing urine biomarker discovery.

Authors:  Michael Harpole; Justin Davis; Virginia Espina
Journal:  Expert Rev Proteomics       Date:  2016-06       Impact factor: 3.940

4.  Dysphagia unveiling systemic immunoglobulin light-chain amyloidosis with multiple myeloma.

Authors:  Juan Gonzalez; Ahsan Wahab; Kavitha Kesari
Journal:  BMJ Case Rep       Date:  2018-10-21

5.  Cellulose Acetate Membrane Electrophoresis Based Urinary Proteomics for the Identification of Characteristic Proteins.

Authors:  Aki Nakayama; Ryo Kubota; Minoru Sakatsume; Hidenori Suzuki; Akira Katayama; Kiyoko Kanamori; Kiyoko Shiba; Shiro Iijima
Journal:  J Clin Lab Anal       Date:  2015-10-10       Impact factor: 2.352

6.  Serum N-Glycans: A New Diagnostic Biomarker for Light Chain Multiple Myeloma.

Authors:  Jie Chen; Meng Fang; Yun-Peng Zhao; Chang-Hong Yi; Jun Ji; Cheng Cheng; Meng-Meng Wang; Xing Gu; Quan-Sheng Sun; Xiao-Ling Chen; Chun-Fang Gao
Journal:  PLoS One       Date:  2015-06-15       Impact factor: 3.240

7.  Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio.

Authors:  Gurmukh Singh
Journal:  J Clin Med Res       Date:  2016-11-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.